Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02024555 · ClinicalTrials.gov registry record · Phase 2
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
A Phase 2 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT02024555 is a Phase 2 study that has completed, run by Vanderbilt University. The registered enrollment target is 97 participants.
The verdict
NCT02024555, a Phase 2 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
The primary purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. We suspect that the CLEAR regimen will improve the absolute FVC percent predicted in chronic pulmonary sarcoidosis participants.
Interventions
- DRUG Placebo
- DRUG Azithromycin
- DRUG Ethambutol
- DRUG Rifampin
- DRUG Levofloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02024555
The ClinicalTrials.gov registry entry for NCT02024555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02024555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02024555 about?
NCT02024555 is a clinical study titled "Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis". The primary purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. We suspect that the CLEAR regimen will improve the absolute FVC percent predicted in chronic pulmonary sarcoidosis participants.
What is the current status of trial NCT02024555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2014-03. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT02024555?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG), Ethambutol (DRUG), Rifampin (DRUG), Levofloxacin (DRUG).
Who is sponsoring clinical trial NCT02024555?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.